Market Cap 10.61B
Revenue (ttm) 2.46B
Net Income (ttm) 367.52M
EPS (ttm) N/A
PE Ratio 26.59
Forward PE N/A
Profit Margin 14.93%
Debt to Equity Ratio 0.41
Volume 300
Avg Vol 692
Day's Range N/A - N/A
Shares Out 356.00M
Stochastic %K 55%
Beta 0.42
Analysts Strong Sell
Price Target $380.00

Company Profile

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 46 86 97 20 00
Address:
Norra Stationsgatan 93A, Stockholm, Sweden
Latest News on BIOVF
No data available.